Quercetin and doxorubicin co-delivery using β-cyclodextrin nanocarrier overcomes multi-drug resistance in cancer cells via targeting Akt/NF-κB/ABCB1 signaling pathway
Author:
Funder
Rashtriya Uchchatar Shiksha Abhiyan
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s42247-024-00845-4.pdf
Reference65 articles.
1. S. Ashique, M. Bhowmick, R. Pal, H. Khatoon, P. Kumar, H. Sharma et al., Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success. Adv. Cancer Biol. - Metastasis 2024
2. M. Feyzizadeh, A. Barfar, Z. Nouri, M. Sarfraz, P. Zakeri-Milani, H. Valizadeh, Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery. Expert Opin. Drug Discov 2022
3. R. Sawpari, S. Samanta, J. Banerjee, S. Das, S.S. Dash, R. Ahmed et al., Recent advances and futuristic potentials of nano-tailored doxorubicin for prostate cancer therapy. J. Drug Deliv Sci. Technol. 2023
4. D. Patel, N. Sethi, P. Patel, S. Shah, K. Patel, Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: a comprehensive review. Eur. J. Pharm. Biopharm. 2024
5. P. Bharathiraja, P. Yadav, A. Sajid, S.V. Ambudkar, N.R. Prasad, Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer. Drug Resist. Updat 2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3